Comparative Effectiveness Bill Could Mean Opportunities For OTC Sponsors
This article was originally published in The Tan Sheet
Executive Summary
Interest on Capitol Hill in comparative effectiveness research could lead to opportunities for marketers of OTC drugs that compete with prescription drugs or other interventions
You may also be interested in...
Momentum Builds To Move Comparative Effectiveness From Idea To Action
Drug and medical device industry efforts to restrict comparative effectiveness research from morphing into outright cost comparisons might be a losing battle, according to speakers at an industry conference
Momentum Builds To Move Comparative Effectiveness From Idea To Action
Drug and medical device industry efforts to restrict comparative effectiveness research from morphing into outright cost comparisons might be a losing battle, according to speakers at an industry conference
Momentum Builds To Move Comparative Effectiveness From Idea To Action
Drug and medical device industry efforts to restrict comparative effectiveness research from morphing into outright cost comparisons might be a losing battle, according to speakers at an industry conference